Modulation of Resistance to antiangiogenic therapy: A clinical trial with correla

抗血管生成治疗耐药性的调节：correla 的临床试验

• 批准号: 7978091
• 负责人: JOHN F DE GROOT
• 金额: $ 32.79万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-16 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7978091
• 关键词: Angiogenesis Inhibitors; Angiogenic Factor; Biological Markers; Blood Vessels; Bone Marrow; Bone Marrow Cells; CSF3 gene; CXCL1 gene; Cells; Cerebral Edema; Chronic; Clinical; Clinical Data; Clinical Trials; Clinical Trials Design; Data; Development; Dose; Drug Delivery Systems; Effectiveness; Enrollment; Fibroblast Growth Factor; Frequencies; Future; Glioblastoma; Glioma; Growth; Histologic; Human; Hypoxia; IL8RB gene; Infiltration; Institution; Laboratories; Lomustine; MMP9 gene; Macrophage Colony-Stimulating Factor; Measurement; Measures; Mediating; Mediator of activation protein; Modeling; Monitor; Myeloid Cells; Neutrophil Infiltration; Operative Surgical Procedures; Outcome; Pathologic; Patients; Peripheral; Phase II Clinical Trials; Plasma; Population; Progression-Free Survivals; Randomized; Recruitment Activity; Recurrence; Reporting; Resistance; Resistance development; Sampling; Schedule; Specimen; Time; Tissues; VEGF Trap; Vascular Endothelial Cell; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors; Vascular Permeabilities; Vascular Proliferation; Xenograft Model; angiogenesis; arm; bevacizumab; chemokine; cohort; cyclohexylchloroethylnitrosourea; granulocyte; improved; in vivo; inhibitor/antagonist; macrophage; monocyte; monocyte colony stimulating factor; neoplastic cell; neutrophil; novel; peripheral blood; phase 2 study; pre-clinical; prevent; public health relevance; rapid growth; receptor; resistance mechanism; response; therapy development; therapy resistant; tumor; tumor growth; tumor progression

DESCRIPTION (provided by applicant): Vascular proliferation is a pathologic hallmark of glioblastoma and studies have shown that the expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) is one mechanism by which tumors induce the formation of new blood vessels. Antiangiogenic therapy has been shown to rapidly decrease vascular permeability, reduce cerebral edema, and prolong progression free survival (PFS) in some patients with recurrent glioblastoma. However, patients with intrinsic resistance do not benefit from anti-VEGF therapy and those that initially respond acquire resistance limiting the long-term effectiveness of this approach. The mechanisms of resistance to anti-VEGF therapy are potentially many but recent reports suggest that bone marrow derived cells (BMDCs) may be important mediators of resistance. We have developed a novel clinical trial designed to potentially modulate the development of glioblastoma resistance to bevacizumab. Patients with recurrent glioblastoma will be randomized to receive standard dose bevacizumab or low-dose bevacizumab combined with lomustine given on day 3 during the "normalization window" to maximize drug delivery to tumor. The lower dose of bevacizumab will be utilized to both improve drug delivery and to prevent or delay the development of severe hypoxia which we have shown to be a prominent feature of glioblastoma tumors treated with chronic anti-VEGF therapy. To evaluate potential modulators of glioblastoma sensitivity and resistance to anti-VEGF therapy, this trial will assess changes in circulating chemokines and myeloid cells in the standard dose versus low dose arms. In Aim 1, we will determine if baseline plasma levels of monocytic and granulocytic chemokines are predictive of response to anti-VEGF therapy. Aim 2 will assess the recruitment of myeloid cells following anti-VEGF therapy. Aim 3 will assess the association between plasma chemokines, the number of myeloid cells infiltrated into glioblastoma samples and histologic markers of vascular proliferation at the time of surgery for recurrent glioblastoma. These studies are critical to establish which biomarkers are useful in predicting response and monitoring treatment progress, as well as for forming a baseline for future trials that incorporate therapies targeting myeloid cell populations. Inclusion of biomarker measurements into this phase II study represent unique strengths of our institution and will enhance our ability to assess the potential efficacy of an alternative bevacizumab dosing schedule in a multidimensional manner. PUBLIC HEALTH RELEVANCE: Despite the promising radiographic responses seen in patients with recurrent glioblastoma treated with antiangiogenic therapy, the long term effectiveness of this therapy remains limited by the development of resistance. Our clinical trial will attempt to modulate and delay the development of resistance to anti-VEGF therapy while exploring plasma chemokines and the myeloid cells they recruit as predictive markers of sensitivity and resistance to therapy.

描述（由申请人提供）：血管增生是胶质母细胞瘤的病理标志，研究表明促血管生成因子（如血管内皮生长因子（VEGF））的表达是肿瘤诱导新血管形成的一种机制。抗血管生成治疗已被证明可以快速降低血管通透性，减轻脑水肿，并延长一些复发性胶质母细胞瘤患者的无进展生存期（PFS）。然而，具有内在抗性的患者不能从抗VEGF治疗中获益，并且那些最初有反应的患者获得抗性，限制了这种方法的长期有效性。抗VEGF治疗的耐药机制可能有很多，但最近的报告表明，骨髓来源的细胞（BMDCs）可能是重要的耐药介质。我们已经开发了一种新的临床试验，旨在潜在地调节胶质母细胞瘤对贝伐单抗的耐药性的发展。复发性胶质母细胞瘤患者将随机接受标准剂量贝伐珠单抗或低剂量贝伐珠单抗联合洛莫司汀，在“正常化窗口”期间在第3天给予，以最大限度地向肿瘤递送药物。较低剂量的贝伐珠单抗将用于改善药物递送和预防或延迟严重缺氧的发展，我们已经证明严重缺氧是用慢性抗VEGF治疗的胶质母细胞瘤肿瘤的突出特征。为了评价胶质母细胞瘤敏感性和抗VEGF治疗抗性的潜在调节剂，本试验将评估标准剂量组与低剂量组中循环趋化因子和骨髓细胞的变化。在目标1中，我们将确定单核细胞和粒细胞趋化因子的基线血浆水平是否可预测抗VEGF治疗的反应。目的2将评估抗VEGF治疗后骨髓细胞的募集。目的3将评估复发性胶质母细胞瘤手术时血浆趋化因子、浸润到胶质母细胞瘤样本中的髓样细胞数量和血管增殖的组织学标志物之间的相关性。这些研究对于确定哪些生物标志物可用于预测反应和监测治疗进展，以及为未来纳入靶向骨髓细胞群体的治疗的试验形成基线至关重要。将生物标志物测量纳入这项II期研究代表了我们机构的独特优势，并将增强我们以多维方式评估替代贝伐珠单抗给药方案的潜在疗效的能力。 公共卫生相关性：尽管在接受抗血管生成治疗的复发性胶质母细胞瘤患者中观察到有希望的放射学反应，但这种治疗的长期有效性仍然受到耐药性发展的限制。我们的临床试验将试图调节和延迟对抗VEGF治疗的耐药性的发展，同时探索血浆趋化因子和它们招募的髓样细胞作为对治疗的敏感性和耐药性的预测标志物。